Additionally, our study found that CD2665, one of the RARγ antagonist, inhibited TNFAIP3 expression in ESCC‐TRCs, indicating that TNFAIP3 may function as a downstream target regulated by RARγ. The gene discussed is TNFAIP3; the disease is esophageal squamous cell carcinoma.